105 results
DEFA14A
VIR
Vir Biotechnology Inc
14 May 24
Additional proxy soliciting materials
4:05pm
Research and Development Authority (BARDA); the Company’s use of artificial intelligence and machine learning in its efforts to engineer next-generation … proteins and in other research and development efforts; the timing and amount of actual expenses, including, without limitation, the Company’s anticipated
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
(ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50122C00081.
◦VIR-2981, an investigational … of sotrovimab.
Research and Development Expenses (R&D): R&D expenses for the first quarter of 2024 were $100.1 million, which included $13.6 million of non
8-K
EX-99.1
VIR
Vir Biotechnology Inc
18 Apr 24
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
8:44am
as a biotech executive and in research and development leadership roles to the industry. He is currently President and Chief Executive Officer, and a member … , and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may
8-K
EX-99.1
fg6klwk
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
noqgros
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
S-3ASR
v8p98qfs6
3 Nov 23
Automatic shelf registration
4:33pm
8-K
EX-99.1
37skarhtt9mucqa5d
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
faotxgznkrtr0upt
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
8-K
EX-99.1
eymse0z332 dbu
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
obds1voofcgl9r56ul
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
EX-99.1
vhb 7gjssit6
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am